Sintx Technologies, Inc. (SINT)
NASDAQ: SINT · Real-Time Price · USD
3.480
+0.130 (3.88%)
At close: Oct 21, 2025, 4:00 PM EDT
3.500
+0.020 (0.57%)
After-hours: Oct 21, 2025, 7:55 PM EDT
Sintx Technologies Revenue
Sintx Technologies had revenue of $151.00K in the quarter ending June 30, 2025, a decrease of -82.42%. This brings the company's revenue in the last twelve months to $1.86M, down -40.47% year-over-year. In the year 2024, Sintx Technologies had annual revenue of $2.89M with 9.90% growth.
Revenue (ttm)
$1.86M
Revenue Growth
-40.47%
P/S Ratio
2.95
Revenue / Employee
$93,050
Employees
20
Market Cap
12.48M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.89M | 260.00K | 9.90% |
Dec 31, 2023 | 2.63M | 1.07M | 68.29% |
Dec 31, 2022 | 1.56M | 955.00K | 157.59% |
Dec 31, 2021 | 606.00K | 12.00K | 2.02% |
Dec 31, 2020 | 594.00K | -95.00K | -13.79% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SINT News
- 1 day ago - SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System - GlobeNewsWire
- 7 days ago - SINTX Technologies Strengthens IP Portfolio with New U.S. Patent Notice of Allowance Covering Antipathogenic Fabrics - GlobeNewsWire
- 6 weeks ago - SINTX Technologies Announces Successful Exercise of Warrants for $3.8 Million Gross Proceeds - GlobeNewsWire
- 6 weeks ago - SINTX Technologies Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform Patent - GlobeNewsWire
- 2 months ago - SINTX Technologies Issues Business Update Following Strategic Realignment, Leadership Expansion, and SiNAPTIC Acquisition - GlobeNewsWire
- 2 months ago - SINTX Technologies Expands Silicon Nitride Platform into Hybrid CFR-PEKK Trauma Plates - GlobeNewsWire
- 4 months ago - SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market - GlobeNewsWire
- 5 months ago - SINTX Technologies Announces Patent Issuance and Formation of Subsidiary to Advance Antimicrobial Applications in the Agribiotech Market - GlobeNewsWire